Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Acetoacetate: Mechanism, Measurement, and Limits
2026-11-22
Acetoacetic acid sodium salt is best interpreted as a chemical form of the ketone body acetoacetate, not as a direct surrogate for endogenous ketogenesis or diabetic ketoacidosis. This editorial separates biochemical mechanism, analytical readouts, and the narrower evidence provided by an isotope-labeling study of an unrelated peptide drug.
From Enzyme Inhibition to LDL Lowering
2026-11-21
How does atorvastatin’s reported biochemical potency relate to downstream cholesterol measurements? The key is to separate direct enzyme inhibition from the cellular feedback and systemic processes that ultimately influence plasma LDL and clinical outcomes.
How BCMA–CD3 Binding Can Drive T-Cell Cytotoxicity
2026-11-20
A BCMA–CD3 bispecific antibody can be understood as a molecular bridge between a target cell and a T cell. The documented mechanism supports interpretation of the sequence from dual recognition to T-cell activation and target-cell lysis, but it does not establish quantitative potency, comparative performance, or clinical outcomes.
How Dual-Target CAR-T Addresses NSCLC Heterogeneity
2026-11-20
A 2026 preclinical study tested whether simultaneous recognition of CD276 and NKG2D ligands could reduce antigen escape in non-small cell lung cancer. Its Bicephali CAR-T platform improved tumor control, survival, immune-synapse formation, and metabolic fitness in cellular and mouse models, but the evidence remains model-specific and does not establish clinical safety or efficacy.
What Does a Selective PTP1B Ki Show?
2026-11-19
A reported Ki of 0.29 μM indicates biochemical inhibition of PTP1B and a strong selectivity contrast against the phosphatases included in the documented comparison panel. It supports a mechanistic hypothesis about phosphorylation-dependent insulin signaling, but does not by itself establish cellular pathway modulation, metabolic benefit, or clinical efficacy.
How Thioridazine Links Targets to Readouts
2026-11-19
Thioridazine HCl is documented as an inhibitor of D2 and D4 dopamine receptors and calcium-channel proteins. Interpreting these annotations requires separating molecular target effects from system-level outcomes such as altered dopaminergic sensitivity or hypotension.
ENO1, Macrophage Metabolism, and Cardiac Repair
2026-11-18
A preclinical study examines whether ENO1 links glycolytic remodeling to inflammatory macrophage behavior after myocardial infarction and tests an acid-responsive nanocarrier for macrophage-directed siRNA delivery. The reported findings connect ENO1 silencing with altered lactate–KLF4 signaling, reduced inflammatory features, and improved cardiac tissue measures in mice, while leaving important translational questions open.
When Context Reframes a Cancer Result
2026-11-18
A CCR7–Notch1 study in mammary tumor cells shows why genetic background, cellular subpopulation, pathway readout, and assay definition determine what a cancer result can legitimately mean.
What AC-262536 Binding Affinity Can Show
2026-11-17
A low-nanomolar androgen receptor binding claim identifies a plausible molecular starting point for studying AC-262536, but it does not by itself establish selective signaling, tissue-specific anabolic effects, safety, or clinical benefit.
(R)-MG132 and the HNRNPU–PHGDH Axis
2026-11-17
A source-grounded analysis separates the cervical-cancer study’s evidence for HNRNPU K181 lactylation from the interpretive role of (R)-MG132 as a low-activity proteasome-control compound.
IRP2, TFEB, and Macrophage Antimicrobial Defense
2026-11-16
A 2024 mouse and macrophage study connects IRP2 loss to defective lysosomal regulation, impaired bacterial clearance, and liver abscess after intestinal barrier injury. Its strongest evidence comes from concordant global and myeloid-cell genetic models, cell-based clearance assays, and pathway perturbations linking HIF2α, lactate metabolism, and TFEB localization. Human inflammatory bowel disease samples support clinical concordance, but they do not establish causality or determine how broadly the mechanism applies.
How Astragaloside IV Links Signals to Injury
2026-11-16
Astragaloside A, also known as Astragaloside IV, is described as a model-dependent modulator of TGF-β/Smad and MAPK-associated injury signaling. The documented findings connect pathway changes with renal fibrosis and myocardial injury readouts, while leaving direct molecular binding, pathway exclusivity, and clinical relevance unresolved.
What NS3694 Reveals About Apoptosome Assembly
2026-11-15
NS3694 is documented as an inhibitor of cytochrome c-driven apoptosome formation rather than a broad direct inhibitor of caspase enzymes. The reported findings support a pathway-level mechanism centered on Apaf-1–caspase-9 complex assembly, while leaving important questions about direct molecular binding, cellular generality, and in vivo relevance unresolved.
How Miransertib Readouts Map to Akt Biology
2026-11-14
Miransertib is described as an allosteric inhibitor of Akt1, Akt2, and Akt3. Its reported biochemical potency, reduced Akt-pathway phosphorylation, and genotype-associated antiproliferative pattern form a coherent mechanistic picture, while remaining model-specific rather than a general efficacy claim.
What GSK3 Inhibition Can—and Cannot—Show
2026-11-13
How can a biochemical kinase interaction relate to tau phosphorylation and antidepressant-like behavior? The documented evidence supports a mechanistic chain from ATP-competitive GSK3 inhibition to a site-specific cellular tau readout and a rodent behavioral phenotype, while leaving important questions about selectivity, causality, and clinical relevance.